Novo Nordisk A/S ADR (NVO) Stock Price, Quote & News

Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products i...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 45 44 44 88 88

Website: www.novonordisk.com

Address:

Novo Alle 1, Bagsvaerd, Denmark

Len44 Feb. 4 at 3:24 AM

$NVO the obesity market is ginormous. I don’t understand why there isn’t plenty of money to be made by both LLY and NVO??

0 · Reply

TheonetrueJester Feb. 4 at 3:18 AM

$NVO

0 · Reply

scotttrader213 Feb. 4 at 3:18 AM

$NVO Blood bath on aisle 9. $NVO, has rebounded before, will be interesting, to see if it subs under 40.00. I’m looking to add more in the dip

0 · Reply

BIOTECH_GURU Feb. 4 at 3:18 AM

$NVO PE ratio of 13?! 😂😂😂 buy the dip dumbass.

0 · Reply

mikesterz7 Feb. 4 at 3:12 AM

$NVO Novo leads early in oral obesity drugs, while Lilly counters with a strong injectable franchise and an oral pill nearing approval.

0 · Reply

Joeblow696969 Feb. 4 at 3:00 AM

$NVO @Ahaddm he’s Persian I wouldn’t expect anything less, the fucker . They are scumbags

0 · Reply

StocktwitsNews Feb. 4 at 2:57 AM

Novo Nordisk Vs Eli Lilly: Which Big Pharma Stock Has More Upside This Year Amid Earnings Season? $NVO $LLY https://stocktwits.com/news/equity/markets/novo-nordisk-vs-eli-lilly-which-big-pharma-stock-has-more-upside-this-year-amid-earnings-season/cZbSmVNR4mH

1 · Reply

TheStockShrewd Feb. 4 at 2:56 AM

Am I wrong or is this gonna impact $LLY as well? Seems like $NVO isn’t the only one who may have to cut guidance.

0 · Reply

KatAtron Feb. 4 at 2:38 AM

$NVO @Prit89 congratulations! Your post, which was very well thought out and informative was featured. Basically, whenever anyone goes on this form, they see your post first. This is why some people are saying that you paid for it. You can’t pay for this. Congratulations and thank you for your post.

0 · Reply

RADRN Feb. 4 at 2:34 AM

$NVO Read the latest article on Seeking Alpha. NVO now has a structural margin crisis- lower margin Oral Wegovy cannibalizes its high margin injectable business. This is not an opportunity. This is will go much lower.

0 · Reply

Novo Nordisk: Compressing Margins And Collapsing Guidance Confirm Sell Thesis

Feb 3, 2026, 2:39 PM EST - 7 hours ago

Novo Nordisk CEO on 2026 Forecast and GLP-1 Pricing

Feb 3, 2026, 1:56 PM EST - 8 hours ago

Novo Nordisk Stock Falls As 2026 Outlook Signals Pricing Pressure, Slowing Sales

Feb 3, 2026, 1:43 PM EST - 8 hours ago

Novo Nordisk's stock tumbles as drugmaker lays out case for declining sales in 2026

Feb 3, 2026, 1:37 PM EST - 8 hours ago

Novo Nordisk stock tumbles 15% despite strong earnings: here's what spooked investors

Feb 3, 2026, 1:27 PM EST - 8 hours ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR LLY PFE VKTX

Feb 3, 2026, 12:37 PM EST - 9 hours ago

Wegovy maker Novo Nordisk appoints Jamey Millar head of its US business

Feb 3, 2026, 12:18 PM EST - 9 hours ago

Wegovy Maker Novo Nordisk Forecasts Sales Decline in 2026

Feb 3, 2026, 12:06 PM EST - 10 hours ago

Novo Nordisk shares tumble 11% after company forecasts sales declines this year

Feb 3, 2026, 12:04 PM EST - 10 hours ago

Novo Nordisk Posts Better-Than-Expected 2025 Sales. Stock Sinks.

Feb 3, 2026, 11:59 AM EST - 10 hours ago

Novo Nordisk warns of 2026 sales decline

Feb 3, 2026, 11:37 AM EST - 10 hours ago

Novo Nordisk releases 2026 sales and operating profit outlook

Feb 3, 2026, 12:29 AM EST - 21 hours ago

Sleep device maker ResMed ramps up doctor outreach to tap Ozempic surge

RMD

Feb 2, 2026, 11:05 AM EST - 1 day ago

Novo Nordisk says CagriSema outperforms semaglutide in late-stage trial of type-2 diabetes patients

Feb 2, 2026, 10:43 AM EST - 1 day ago

Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial

Feb 2, 2026, 6:07 AM EST - 1 day ago

Obesity market sales potential tightens as Novo and Lilly enter new era

LLY

Jan 30, 2026, 12:31 PM EST - 4 days ago

5 Stocks Primed for a Turnaround in 2026

ABNB CMCSA DECK UNH

Jan 30, 2026, 11:09 AM EST - 4 days ago

Novo Nordisk: Momentum Meets Headwinds Before Earnings (Upgrade)

Jan 30, 2026, 9:18 AM EST - 4 days ago

New play in Denmark charts Novo Nordisk's weight loss boom

Jan 30, 2026, 7:30 AM EST - 4 days ago

Novo's Wegovy pill tracks over 26,000 prescriptions

Jan 30, 2026, 3:48 AM EST - 4 days ago

Novo Nordisk's China President Zhou to step down in March

Jan 28, 2026, 12:39 PM EST - 6 days ago

Novo Nordisk: Investors May Be In For An Earnings Surprise

Jan 28, 2026, 6:07 AM EST - 6 days ago

Exclusive: Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows

LLY

Jan 26, 2026, 10:30 PM EST - 7 days ago

GreensKeeper Value Fund Q4 2025 Portfolio Update: Long-Term Winners

A ADBE AXP B C CBOE CHKP

Jan 26, 2026, 11:21 AM EST - 8 days ago

Novo Nordisk: The Q4 Setup Favors Another Beat (Earnings Preview)

Jan 25, 2026, 6:26 AM EST - 9 days ago

Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog

LLY

Jan 23, 2026, 3:41 PM EST - 11 days ago

Novo Nordisk: This Run Is Just Getting Started

Jan 23, 2026, 9:12 AM EST - 11 days ago

Novo's 500% Pill Pop: Wegovy Just Obliterated Every GLP-1 Launch Record

Jan 23, 2026, 7:32 AM EST - 11 days ago

Novo's Wegovy pill tracks 18,410 prescriptions for first full week since launch

Jan 23, 2026, 7:00 AM EST - 11 days ago

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

LLY

Jan 22, 2026, 6:18 PM EST - 12 days ago

Final Trade: SII, C, SMH, NVO

SMH C SII

Jan 22, 2026, 9:00 AM EST - 12 days ago

Sesame Launches Wegovy® Pill Through Collaboration With Novo Nordisk

Jan 21, 2026, 11:20 AM EST - 13 days ago

Novo Nordisk: How Inspiring New CEO Will Take Fight To Key Rival Eli Lilly In 2026

Jan 21, 2026, 9:15 AM EST - 13 days ago

Novo: Back From The Dead

Jan 20, 2026, 12:18 PM EST - 14 days ago

Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry

PFE

Jan 20, 2026, 9:28 AM EST - 14 days ago

Novo Nordisk expands diabetes cell therapy partnership with Aspect Biosystems

Jan 20, 2026, 8:00 AM EST - 14 days ago

Novo Nordisk Aims to Set Ozempic Apart From Other GLP-1s in New Ad Campaign

Jan 16, 2026, 12:15 PM EST - 18 days ago

Trump's Greenland ambition: stocks that may face tariff shock in 2026

Jan 16, 2026, 12:07 PM EST - 18 days ago

Novo Nordisk's Newly Approved Weight Loss Pill Shows Record Prescription Data

Jan 16, 2026, 11:30 AM EST - 18 days ago

Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid' launch

Jan 16, 2026, 9:26 AM EST - 18 days ago

Novo Nordisk's Wegovy Weight Loss Shot Approved At Higher Dose in U.K.

Jan 16, 2026, 7:43 AM EST - 18 days ago

Novo's Wegovy pill tracks 3,071 prescriptions in first days of launch

Jan 16, 2026, 7:37 AM EST - 18 days ago

Novo Nordisk Stock Rises After U.K. Approves Higher Wegovy Dose for Weight Loss

Jan 16, 2026, 6:50 AM EST - 18 days ago

Novo shares jump 7% ahead of US prescription data for Wegovy pill

Jan 14, 2026, 12:08 PM EST - 20 days ago

Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference

Jan 13, 2026, 3:35 PM EST - 21 days ago

Novo Nordisk A/S (NOVO:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 1:54 PM EST - 21 days ago

Novo Nordisk flags near-term headwinds in international markets

Jan 12, 2026, 7:48 PM EST - 22 days ago

Novo Nordisk CEO: Wegovy not only reduces your weight, but it also shows cardiovascular benefits

Jan 12, 2026, 7:41 PM EST - 22 days ago

Novo Nordisk CEO: People have been waiting for a GLP-1 pill

Jan 12, 2026, 6:29 PM EST - 22 days ago

Novo Nordisk CEO explains why new GLP-1 pill expands access to the weight loss drugs

Len44 Feb. 4 at 3:24 AM

$NVO the obesity market is ginormous. I don’t understand why there isn’t plenty of money to be made by both LLY and NVO??

0 · Reply

TheonetrueJester Feb. 4 at 3:18 AM

$NVO

0 · Reply

scotttrader213 Feb. 4 at 3:18 AM

$NVO Blood bath on aisle 9. $NVO, has rebounded before, will be interesting, to see if it subs under 40.00. I’m looking to add more in the dip

0 · Reply

BIOTECH_GURU Feb. 4 at 3:18 AM

$NVO PE ratio of 13?! 😂😂😂 buy the dip dumbass.

0 · Reply

mikesterz7 Feb. 4 at 3:12 AM

$NVO Novo leads early in oral obesity drugs, while Lilly counters with a strong injectable franchise and an oral pill nearing approval.

0 · Reply

Joeblow696969 Feb. 4 at 3:00 AM

$NVO @Ahaddm he’s Persian I wouldn’t expect anything less, the fucker . They are scumbags

0 · Reply

StocktwitsNews Feb. 4 at 2:57 AM

1 · Reply

TheStockShrewd Feb. 4 at 2:56 AM

Am I wrong or is this gonna impact $LLY as well? Seems like $NVO isn’t the only one who may have to cut guidance.

0 · Reply

KatAtron Feb. 4 at 2:38 AM

0 · Reply

RADRN Feb. 4 at 2:34 AM

0 · Reply

Ahaddm Feb. 4 at 2:31 AM

$NVO The CEO: 1. Were not gonna make as much money next yr. 2. Lots of competition next year. 3. Our US sales are gonna take a dive next yr. 4. We will be losing exclusivity for the semaglutide molecule in certain markets in international operations next yr. 5. Post all this the day before earnings was to be released so no one can get out if they wanted. 6. With all that great news, throw in a buy back ho hum to get no traction. Is there a more blatant, even possibly criminal act a CEO can perform to show us he purposefully tanking the stock to make himself look good in the years to come?

0 · Reply

ARPH Feb. 4 at 2:12 AM

$NVO Added some here at $49

0 · Reply

Fergus20 Feb. 4 at 2:10 AM

$NVO why does this have a higher market cap than $BCRX?

0 · Reply

WallStreetBuyDip Feb. 4 at 1:57 AM

watching how $NVO moves. will buy at low H% like shown here

0 · Reply

nvda_wins_at_the_end Feb. 4 at 1:45 AM

$NVO why does it go up after 8pm? Still holding my 1k shares, dont want it to be fake move.

1 · Reply

Showyouthemoney Feb. 4 at 1:41 AM

$NVO Hey All, Pretty f*cked up day….. I have been posting a lot in frustration about what went down today, and I have been pretty critical of the CEO {still am). But this is what I finally have concluded actually happened. Gemini helped me arrive at this. - The company produced its final guidance for ER and found that their forecast was materially worse than analysts had modeled. - They decided to pre-release after Danish market closed. Probably to get the bad news out early, so the shock could wear off before actual ER and conf. call tomorroe. - They contacted Bloomberg and had the CFO (Knudsen) cued up for an interview. - They notified the exchange that were about to release material information. - The exchange halted trading for “news” - They released the Pre-Er and the stock resumed trading - Knudsen immediately went on Bloomberg. Because they had pre-released… the quiet period was now over and Knudsen was free to speak

1 · Reply

no_cry Feb. 4 at 1:41 AM

$NVO huge discount. Would be back $60+ this month

1 · Reply

Estimize Feb. 4 at 1:40 AM

$NVO reported - EPS and - revenue for Q4. http://www.estimize.com/intro/nvo?chart=historical&metric_name=eps&utm_content=NVO&utm_medium=act

0 · Reply

Yolo2323 Feb. 4 at 1:34 AM

$NVO idiots that sold. This is going $100+

1 · Reply

Itzx3ro Feb. 4 at 1:29 AM

$NVO buying heavy if this opens under $50 tomorrow. Thank you panic sellers for giving us the opportunity to buy such a high-quality company on a big sale!

0 · Reply

WallStreetBuyDip Feb. 4 at 1:21 AM

Comparing trending tickers $NVO vs $PYPL: NVO dropped to $50.30, down 14.64% on a significantly high volume of 69.3M shares, nearly 5x its average. Meanwhile, PYPL fell even more sharply to $41.70, a 20.31% decrease, with a trading volume of 141.1M shares, about 10x its usual volume. Although both stocks experienced substantial declines and high trading volumes, PYPL's larger percentage drop and even higher relative volume suggest a more dramatic market reaction compared to NVO.

0 · Reply

TheStockShrewd Feb. 4 at 1:20 AM

$NVO bid for $VKTX please 🙏🙏🙏🙏🙏🙏

0 · Reply

Market Cap	265.35B
Revenue (ttm)	42.11B
Net Income (ttm)	14.64B
EPS (ttm)	N/A
PE Ratio	15.53
Forward PE	18.04
Profit Margin	34.78%
Debt to Equity Ratio	0.60

Volume	69,933,200
Avg Vol	21,117,727
Day's Range	N/A - N/A
Shares Out	4.47B
Stochastic %K	2%
Beta	0.66
Analysts	Sell
Price Target	$57.16